ImmPACT Bio Overview
- Year Founded
-
2017
- Status
-
Acquired/Merged
- Employees
-
108
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$93.7M
ImmPACT Bio General Information
Description
Operator of a cell therapy company intended to discover transformative chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company assures tumor specificity by inducing cytotoxicity only upon engagement of the CAR-T cell with a tumor cell, but not with any normal cell, enabling doctors to differentiate cancerous from noncancerous tissues that affect the treatment thereby mitigating the safety risks associated with current CAR-T technologies.
Contact Information
Website
www.immpact-bio.comCorporate Office
- 8501 Fallbrook Avenue
- Suite 200
- West Hills, CA 91304
- United States
Corporate Office
- 8501 Fallbrook Avenue
- Suite 200
- West Hills, CA 91304
- United States
ImmPACT Bio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Merger/Acquisition | 31-Oct-2024 | $93.7M | Completed | Generating Revenue | ||
| 3. Later Stage VC (Series B) | 01-Apr-2024 | Completed | Generating Revenue | |||
| 2. Early Stage VC (Series A) | 18-Aug-2020 | $18M | $18M | Completed | Generating Revenue | |
| 1. Accelerator/Incubator | Completed | Startup |
ImmPACT Bio Comparisons
Industry
Financing
Details
ImmPACT Bio Competitors (3)
One of ImmPACT Bio’s 3 competitors is Carisma Therapeutics, a Formerly VC-backed company based in Philadelphia, PA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Carisma Therapeutics | Formerly VC-backed | Philadelphia, PA | ||||
| AVEO Oncology | Formerly VC-backed | Boston, MA | ||||
| Atara Biotherapeutics | Formerly VC-backed | Thousand Oaks, CA |
ImmPACT Bio Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
ImmPACT Bio Patents
ImmPACT Bio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2024192134-A1 | Bispecific cars for the treatment of lupus and autoimmune diseases | Inactive | 13-Mar-2023 | ||
| US-20260043004-A1 | Methods of manufacturing chimeric antigen receptor t cells | Pending | 04-Aug-2022 | ||
| WO-2023172991-A2 | Bicistronic inhibitory chimeric antigen receptor (icar)/activating chimeric antigen receptor (acar) constructs for use in cancer therapies | Inactive | 09-Mar-2022 | ||
| WO-2023172991-A3 | Bicistronic inhibitory chimeric antigen receptor (icar)/activating chimeric antigen receptor (acar) constructs for use in cancer therapies | Inactive | 09-Mar-2022 | ||
| WO-2023076912-A2 | Cd4+ and/or cd8+ cell populations comprising icars for use in treatment therapies | Inactive | 26-Oct-2021 | A61K40/11 |
ImmPACT Bio Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
ImmPACT Bio Former Investors (15)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Arkin Capital | Asset Manager | Minority | ||
| Boryung (United States) | PE/Buyout | Minority | ||
| Bukwang Pharmaceutical | Corporation | Minority | ||
| Decheng Capital | Venture Capital | Minority | ||
| Foresite Capital | Growth/Expansion | Minority |
ImmPACT Bio Acquisitions (1)
ImmPACT Bio’s most recent deal was a Merger/Acquisition with Kalthera. The deal was made on 22-Jul-2021.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Kalthera | 22-Jul-2021 | Merger/Acquisition | Biotechnology |
ImmPACT Bio FAQs
-
When was ImmPACT Bio founded?
ImmPACT Bio was founded in 2017.
-
Where is ImmPACT Bio headquartered?
ImmPACT Bio is headquartered in West Hills, CA.
-
What is the size of ImmPACT Bio?
ImmPACT Bio has 108 total employees.
-
What industry is ImmPACT Bio in?
ImmPACT Bio’s primary industry is Drug Discovery.
-
Is ImmPACT Bio a private or public company?
ImmPACT Bio is a Private company.
-
What is the current valuation of ImmPACT Bio?
The current valuation of ImmPACT Bio is .
-
What is ImmPACT Bio’s current revenue?
The current revenue for ImmPACT Bio is .
-
How much funding has ImmPACT Bio raised over time?
ImmPACT Bio has raised $158M.
-
Who are ImmPACT Bio’s investors?
Arkin Capital, Boryung (United States), Bukwang Pharmaceutical, Decheng Capital, and Foresite Capital are 5 of 15 investors who have invested in ImmPACT Bio.
-
Who are ImmPACT Bio’s competitors?
Carisma Therapeutics, AVEO Oncology, and Atara Biotherapeutics are competitors of ImmPACT Bio.
-
When was ImmPACT Bio acquired?
ImmPACT Bio was acquired on 31-Oct-2024.
-
Who acquired ImmPACT Bio?
ImmPACT Bio was acquired by Lyell Immunopharma.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
